EGFR and head and neck squamous cell carcinoma: Their synergistic effect, via a combinative treatment with RSL3 and Cetuximab on ferroptosis- and Cetuximab-resistant HNSCC cells is interesting, which will provide a prospective therapeutic strategy for treating EGFR-resistant HNSCCs.